Biotech Values

[isolution]

Killing or starve a tumor?


Dew, I've just read your post on Yahoo board "Agree. The likelihood is small that CA4P, Avastin, or any anti-angiogenic/VTA drug will work well against many kinds of solid tumors as a monotherapy. In combination with chemotherapy or radiation, however, you have the potential for the formidable inner-outer 1-2 punch you describe. " Combination therapy is being discussed extensively these days and it seems that scientist hesitate for the best strategy. You mught be interested to read this recent PR:

http://www.eurekalert.org/pub_releases/2003-09/uorm-sat091103.php

Also, on a business point of view (a lot less ethical), it is interesting to view the market potential of antiangiogenic molecules as lifetime therapies instead of one shot definitive cure for cancer.
Eventhough I am personnally more in favor of the definitive curing of the cancer, the valuation of a molecule is quite different if you have to take a pill for all your life.